Oncology

X-ray showing colon cancer
#Bowel cancer #Colorectal cancer #Gene mutation #Oncology #University of Delaware

Researchers find common mutation sparks colon tumour growth

A team of researchers from ChristianaCare and the University of Delaware in the US has uncovered that a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal process, causing immature cells to build up, tissue structure to break down and early tumours to form. … Read More

#Cancer Research #Editor's Choice #News

#AI / data analytics / healthtech / informatics #Alzheimer's #Drug discovery #Oncology #Regulatory #Spatial biology

DDW Winter issue out now

The DDW Winter 2025/2026 issue is out now and includes features covering the advances and challenges in blood cancer drug development, how the Baltics is implementing a new action plan for its life sciences sectors, and how spatial epigenetics is unlocking new frontiers for drug discovery.  It also… Read More

#News

Desmoid tumour
#Financing #Oncology #Parabilis Medicines

Parabilis Medicines announces oversubscribed $305m financing

Oncology biopharmaceutical company Parabilis Medicines has announced the successful closing of a $305 million Series F financing.  The round was co-led by RA Capital Management, Fidelity Management & Research Company and Janus Henderson Investors, with participation from new investors including Frazier Life Sciences, Soleus Capital, and a life science-dedicated investment… Read More

#Business & Investment #Cancer Research #News

#CureLab Oncology #DNA #endogene.bio #Endometriosis #Genetics #Junevity #MHRA #Ocular diseases #Oncology #Regulatory #UK government #University of California San Francisco #Women's health

DDW Highlights: 20 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research in women’s health uncovered significant findings related to endometriosis and… Read More

#Podcasts

#CureLab Oncology #DNA #endogene.bio #Endometriosis #Genetics #Junevity #MHRA #Ocular diseases #Oncology #Ovarian cancer #Regulatory #UK government #University of California San Francisco #Women's health

This week in Drug Discovery (12 – 16 January) 

News round-up for 12 – 16 January by Bruno Quinney, Content Team at DDW.  This week in DDW, new research in women’s health has uncovered significant findings related to endometriosis and ovarian cancer. Elsewhere, can ageing be reversed?  The top stories:    Discovery reveals endometriosis is not… Read More

#News

Ovarian cancer cells
#CureLab Oncology #DNA #Oncology #Ovarian cancer

Therapy could increase ovarian cancer survival, paper finds 

A novel DNA-based therapy could increase survival rates for women with platinum-resistant ovarian cancer, a new paper reveals.  A new clinical study, published in the International Journal of Gynecological Cancer, shows the DNA-based therapy Elenagen, when administered in combination with standard chemotherapy drug gemcitabine, significantly extended overall survival… Read More

#Cancer Research #News

Leukaemia
#Amgen #Haematology #Mergers and acquisitions #Oncology

Amgen acquires Dark Blue Therapeutics for $840 million

Oncology biotech Dark Blue Therapeutics has been acquired by Amgen for up to $840 million, including upfront and future milestones.  Dark Blue's lead candidate DBT 3757, currently in IND-enabling studies, represents a first-in-class therapeutic strategy for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), with the potential for producing… Read More

#Business & Investment #News

Cancer cells
#EpiBiologics #Financing #Non-small cell lung cancer (NSCLC) #Oncology

Biotech startup raises $107m to advance oncology candidates 

Biotech startup EpiBiologics has raised $107 million Series B financing to support its pipeline of novel bispecific antibodies.  The financing, co-led by Google Ventures and Johnson & Johnson, will be used to advance candidate EPI-326 into a first-in-human clinical trial for treatment of EGFR-driven lung cancer and head and neck cancer.  EPI-326… Read More

#Business & Investment #News

#Biopharma #Evaluate Pharma #Merck #Mergers and acquisitions #Oncology

M&A boosted biopharma by $36bn at end of 2025, report finds 

A surge in mergers and acquisitions (M&A) boosted the biopharma market by $36 billion at the end of 2025, a new report finds.  Evaluate’s 2026 Preview Report shows $36 billion was generated through M&A last October and November, largely through biotech buyout. The report predicts M&A will continue to play an important role in the… Read More

#Business & Investment #News

Cancer cell
#Cancer #Drug development #ESMO #Liver disease #Oncology

Autotaxin inhibition: unlocking new frontiers in cancers and beyond 

Richard Staines reviews the emergence of autotaxin (ATX) inhibition as a transformative approach in oncology, with the potential to expand into other diseases, including liver malignancies.  Autotaxin (ATX) inhibition is emerging as a promising therapeutic strategy in oncology, with potential relevance to chronic liver disease and beyond. Although early trials in idiopathic pulmonary fibrosis (IPF) faced… Read More

#Exclusive Content

Antibody drug conjugate
#Antibody drug conjugate (ADC) #China #Kelun-Biotech #NMPA #Oncology #Solid tumours

Kelun-Biotech’s ADC IND for solid tumours approved in China

Kelun-Biotech’s Investigational New Drug (IND) application for SKB105 (CR-003), an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumours.  In December 2025, Kelun-Biotech and Crescent Biopharma entered… Read More

#News #Regulatory

#Cell and gene therapy #Gene editing #Immunotherapy #Neurodegenerative disorders #Obesity #Oncology

Which drug discovery breakthroughs made the headlines in 2025?

Diana Turner counts down the biggest DDW news stories of 2025.  10. First use of CAR-T therapy to treat ulcerative colitis In October, a team of physicians at the German Center for Immunotherapy at Erlangen University Hospital succeeded for the first time in treating a 21-year-old female patient with therapy-resistant,… Read More

#Exclusive Content

#Antibody drug conjugate (ADC) #Head and neck cancer #Oncology #Phase I trial #Pyxis Oncology

First-in-concept ADC shows promise in head and neck cancer

Pyxis Oncology has announced positive preliminary data from its ongoing Phase I clinical studies evaluating micvotabart pelidotin (MICVO) in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).   MICVO is an antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the… Read More

#Cancer Research #News

Woman reading on a laptop
#CAR-T #Cell and gene therapy #Flow Cytometry #Oncology #Quantum computing

Your top reads of 2025

With topics as diverse as quantum computing, ion channel drug discovery and antisense oligonucleotides, these were DDW readers’ most-read articles of 2025.  10. We need international partnerships to get new cancer drugs into the clinic On International Clinical Trials Day, Lars Erwig, Director of the Centre for Drug Development at… Read More

#Exclusive Content

#Immunotherapy #Oncology #Oncolytic virus #Viral vectors

Re-engineering oncolytic immunotherapy

Dave Cole, Head of Research, Accession Therapeutics, introduces a replicating viral platform for systemic tumour targeting. Cancer immunotherapy has transformed oncology. Immune checkpoint inhibitors and cell therapies have shown that the immune system can be mobilised to achieve durable tumour control. Yet for most patients, response rates remain modest. Many… Read More

#Exclusive Content